Long-term outcomes of a phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumors of the stomach

被引：0
作者：
Seong-Ho Kong
Yukinori Kurokawa
Jeong-Hwan Yook
Haruhiko Cho
Oh-Kyoung Kwon
Toru Masuzawa
Kyung Hee Lee
Sohei Matsumoto
Young Soo Park
Hiroshi Honda
Seung-Wan Ryu
Takashi Ishikawa
Hye Jin Kang
Kazuhito Nabeshima
Seock-Ah Im
Toshio Shimokawa
Yoon-Koo Kang
Seiichi Hirota
Han-Kwang Yang
Toshirou Nishida
机构：
[1] Seoul National University Hospital,Department of Surgery, Cancer Research Institute
[2] Seoul National University College of Medicine Cancer Research Institute,Department of Gastroenterological Surgery
[3] Osaka University Graduate School of Medicine,Department of Surgery
[4] University of Ulsan College of Medicine Asan Medical Center,Department of Surgery
[5] Kanagawa Cancer Center,Department of Surgery
[6] Kyungpook National University School of Medicine,Department of Surgery
[7] Kyungpook National University Chilgok Hospital,Department of Hemato
[8] Osaka Police Hospital,Oncology
[9] Yeungnam University College of Medicine,Department of Surgery
[10] Nara Medical University,Department of Pathology
[11] University of Ulsan College of Medicine Asan Medical Center,Department of Surgery
[12] Sendai Open Hospital,Department of Surgery
[13] Keimyung University Dongsan Hospital,Department of Surgery
[14] Niigata University Graduate School of Medical and Dental Sciences,Department of Internal Medicine, Korea Institute of Radiological & Medical Sciences
[15] Korea Cancer Center Hospital,Department of Surgery
[16] Tokai University,Department of Internal Medicine
[17] Seoul National University Hospital and Seoul National University College of Medicine Cancer Research Institute,Clinical Study Support Center
[18] Wakayama Medical University Hospital,Department of Oncology
[19] University of Ulsan College of Medicine Asan Medical Center,Department of Surgical Pathology
[20] Hyogo Medical University School of Medicine,Department of Surgery
[21] Japan Community Health Care Organization Osaka Hospital,undefined
来源：
Gastric Cancer | 2023年 / 26卷
关键词：
Gastrointestinal stromal tumor; Imatinib mesylate; Neoadjuvant; Stomach neoplasm;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：775 / 787
页数：12
相关论文
共 125 条
[1]  
Koo DH(2016)Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor Cancer Res Treat 48 1155-1166
[2]  
Ryu MH(2008)Risk stratification of patients diagnosed with gastrointestinal stromal tumor Hum Pathol 39 1411-1419
[3]  
Kim KM(2012)Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts Lancet Oncol 13 265-274
[4]  
Yang HK(2018)Genotype and risk of tumour rupture in gastrointestinal stromal tumour Br J Surg 105 e169-e175
[5]  
Sawaki A(2021)Gastrointestinal stromal tumours Nat Rev Dis Primers 7 22-iii26
[6]  
Hirota S(2014)ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 25 iii21-465
[7]  
Joensuu H(2002)Diagnosis of gastrointestinal stromal tumors: a consensus approach Hum Pathol 33 459-1478
[8]  
Joensuu H(2006)Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis Arch Pathol Lab Med 130 1466-32
[9]  
Vehtari A(2017)Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach Br J Cancer 117 25-1272
[10]  
Riihimäki J(2012)One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial JAMA 307 1265-480
12345678910